Clinical Study

Isa101b-Hn-01-17 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Of Cemiplimab Versus The Combination Of Cemipilmab With Isa101b In The Treatment Of Subjects With Hpv16-Positive Platin-Resistant Oropharyngeal Cancer (Opc)

Posted Date: Jun 10, 2019

  • Investigator: Muhammad Riaz
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

To evaluate if the addition of ISA101b to cemiplimab results in improved overall response rate (ORR) compared to cemiplimab alone

Criteria:

At Least 18 Years Of Age, Recurrent/Metastatic Hpv16+ Oropharyngeal Cancer, Tumor Progression/Reoccurance After Platinum Based Chemotherapy, No Chemo Within 28 Days Of First Study Treatment

Keywords:

Oropharyngeal Cancer, Head And Neck Cancer, Hpv16+

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.